Proteome study of cutaneous lupus erythematosus (CLE) and dermatomyositis skin lesions reveals IL-16 is differentially upregulated in CLE
Tóm tắt
The objective of the study was to explore the disease pathways activated in the inflammatory foci of skin lesions in cutaneous lupus erythematosus (CLE) and dermatomyositis (DM). Skin biopsies acquired from active CLE and DM lesions, patient (PC), and also healthy controls (HC) were investigated. Biopsy sections were examined by a pathologist, inflammatory foci were laser micro-dissected and captured, and proteins within captured tissue were detected in an unbiased manner by mass spectrometry. Protein pathway analysis was performed by the
string-db.org
platform. Findings of interest were confirmed by immunohistochemistry (IHC). Proteome investigation identified abundant expression of interferon-regulated proteins (IRP) as a common feature of CLE and DM. Interleukin (IL)-16 was the only abundant cytokine differentially expressed in CLE compared to DM. Caspase-3, an enzyme that cleaves IL-16 into its active form, was detected in low levels. Significantly higher proportion of IL-16- and caspase-3-positive cells was identified in CLE lesions in comparison with DM, PC, and HC. Proteomic results indicate more abundant complement deposition in CLE skin lesions. Using unbiased mass spectrometry investigation of CLE and DM inflammatory infiltrates, we confirmed that high IRP expression is a common feature of both CLE and DM, while IL-16 is the only differentially expressed cytokine in CLE. IHC confirmed high expression of IL-16 and caspase-3 in CLE. Our novel molecular findings indicate that IL-16 detection could be useful in differential diagnostics between the two conditions that can display similar histopathological appearance. IL-16 could be of interest as a future therapeutic target for CLE.
Từ khóa
Tài liệu tham khảo
Sontheimer RD. Subacute cutaneous lupus erythematosus: a decade’s perspective. Med Clin North Am. 1989;73(5):1073–90. https://doi.org/10.1016/S0025-7125(16)30620-4.
Popovic K, Wahren-Herlenius M, Nyberg F. Clinical follow-up of 102 anti-Ro/SSA-positive patients with dermatological manifestations. Acta Derm Venereol. 2008;88(4):370–5. https://doi.org/10.2340/00015555-0473.
Ghodke-Puranik Y, Niewold TB. Genetics of the type I interferon pathway in systemic lupus erythematosus. Int J Clin Rheumtol. 2013;8(6):657–69. https://doi.org/10.2217/ijr.13.58.
Schultz HY, Dutz JP, Furukawa F, Goodfield MJ, Kuhn A, Lee LA, Nyberg F, Szepietowski JC, Sontheimer RD, Werth VP. From pathogenesis, epidemiology, and genetics to definitions, diagnosis, and treatments of cutaneous lupus erythematosus and dermatomyositis: a report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013. J Invest Dermatol. 2015;135(1):7–12. https://doi.org/10.1038/jid.2014.316.
Vencovsky J, Alexanderson H, Lundberg IE. Idiopathic inflammatory myopathies. Rheum Dis Clin N Am. 2019;45(4):569–81. https://doi.org/10.1016/j.rdc.2019.07.006.
Chen L, Morris DL, Vyse TJ. Genetic advances in systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2017;29(5):423–33. https://doi.org/10.1097/BOR.0000000000000411.
Niewold TB. Advances in lupus genetics. Curr Opin Rheumatol. 2015;27(5):440–7. https://doi.org/10.1097/BOR.0000000000000205.
Järvinen TM, Hellquist A, Koskenmies S, Einarsdottir E, Koskinen LLE, Jeskanen L, Berglind L, Panelius J, Hasan T, Ranki A, Kere J, Saarialho-Kere U. Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus. Exp Dermatol. 2010;19(2):123–31. https://doi.org/10.1111/j.1600-0625.2009.00982.x.
Tsoi LC, Gharaee-Kermani M, Berthier CC, Nault T, Hile GA, Estadt SN, Patrick MT, Wasikowski R, Billi AC, Lowe L, Reed TJ, Gudjonsson JE, Kahlenberg JM. IL18-containing 5-gene signature distinguishes histologically identical dermatomyositis and lupus erythematosus skin lesions. JCI Insight. 2020;5:463.
Jolly M, Kazmi N, Mikolaitis RA, Sequeira W, Block JA. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures. J Am Acad Dermatol. 2013;68(4):618–23. https://doi.org/10.1016/j.jaad.2012.08.035.
Anyanwu CO, Fiorentino DF, Chung L, Dzuong C, Wang Y, Okawa J, Carr K, Propert KJ, Werth VP. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol. 2015;173(4):969–74. https://doi.org/10.1111/bjd.13915.
Lam GKW, Petri M. Assessment of systemic lupus erythematosus. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S120–32.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.
Lundberg IE, Miller FW, Tjärnlund A, Bottai M. Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med. 2016;280(1):39–51. https://doi.org/10.1111/joim.12524.
QuPath. https://qupath.github.io/ Accessed 20 Sept 2020.
Lee S, Kaneko H, Sekigawa I, Tokano Y, Takasaki Y, Hashimoto H. Circulating interleukin-16 in systemic lupus erythematosus. Br J Rheumatol. 1998;37(12):1334–7. https://doi.org/10.1093/rheumatology/37.12.1334.
Idborg H, Eketjäll S, Pettersson S, Gustafsson JT, Zickert A, Kvarnström M, Oke V, Jakobsson P-J, Gunnarsson I, Svenungsson E. TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000260. https://doi.org/10.1136/lupus-2018-000260.
Kawabata K, Makino T, Makino K, Kajihara I, Fukushima S, Ihn H. IL-16 expression is increased in the skin and sera of patients with systemic sclerosis. Rheumatology (Oxford). 2020;59(3):519–23. https://doi.org/10.1093/rheumatology/kez318.
Center DM, Cruikshank WW, Zhang Y. Nuclear pro-IL-16 regulation of T cell proliferation: p27(KIP1)-dependent G0/G1 arrest mediated by inhibition of Skp2 transcription. J Immunol. 2004;172(3):1654–60. https://doi.org/10.4049/jimmunol.172.3.1654.
Ludwiczek O, Kaser A, Koch RO, Vogel W, Cruikshank WW, Tilg H. Activation of caspase-3 by interferon alpha causes interleukin-16 secretion but fails to modulate activation induced cell death. Eur Cytokine Netw. 2001;12(3):478–86.
Faustman D, Li XP, Lin HY, Fu YE, Eisenbarth G, Avruch J, Guo J. Linkage of faulty major histocompatibility complex class I to autoimmune diabetes. Science. 1991;254(5039):1756–61. https://doi.org/10.1126/science.1763324.
Jin M. Unique roles of tryptophanyl-tRNA synthetase in immune control and its therapeutic implications. Exp Mol Med. 2019;51(1):1–10. https://doi.org/10.1038/s12276-018-0196-9.
Velthuis PJ, Kater L, van der Tweel I, la Faille de HB, van Vloten WA: Immunofluorescence microscopy of healthy skin from patients with systemic lupus erythematosus: more than just the lupus band. Ann Rheum Dis 1992, 51:720–725, 6, doi: https://doi.org/10.1136/ard.51.6.720.
Cardinali C, Caproni M, Fabbri P. The utility of the lupus band test on sun-protected non-lesional skin for the diagnosis of systemic lupus erythematosus. Clin Exp Rheumatol. 1999;17(4):427–32.
Jain A, Sharma MC, Sarkar C, Bhatia R, Singh S, Gulati S, Handa R. Detection of the membrane attack complex as a diagnostic tool in dermatomyositis. Acta Neurol Scand. 2011;123(2):122–9. https://doi.org/10.1111/j.1600-0404.2010.01353.x.